Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
8.10
+0.15 (1.89%)
At close: Jun 5, 2025, 4:00 PM
8.10
0.00 (0.00%)
After-hours: Jun 5, 2025, 4:36 PM EDT
Regulus Therapeutics Employees
Regulus Therapeutics had 34 employees as of December 31, 2024. The number of employees increased by 4 or 13.33% compared to the previous year.
Employees
34
Change (1Y)
4
Growth (1Y)
13.33%
Revenue / Employee
n/a
Profits / Employee
-$1,397,735
Market Cap
612.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
RGLS News
- 9 days ago - Novartis announces commencement of tender offer to acquire Regulus Therapeutics - GlobeNewsWire
- 4 weeks ago - Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - PRNewsWire
- 4 weeks ago - REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS - Business Wire
- 5 weeks ago - Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga
- 5 weeks ago - Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga
- 5 weeks ago - Novartis to Acquire Regulus in $1.7 Billion Deal - WSJ
- 5 weeks ago - Novartis to buy Regulus Therapeutics for up to $1.7 billion - Reuters
- 5 weeks ago - Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure - GlobeNewsWire